ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Anika Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$20.22+0.24 (+1.20%)
Close on Oct 19, 2026
- Market cap
- $277.36M
- P/E (TTM)
- –
- Dividend yield
- –
Anika Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Market Cap | $270.60M | $230.55M |
| Enterprise Value | $232.19M | $202.97M |
| PS Ratio | 2.24 | 3.10 |
| PB Ratio | 1.97 | 3.04 |
| P/TBV Ratio | 2.12 | 4.43 |
| P/FCF Ratio | 481.50 | 27.30 |
| P/OCF Ratio | 45.27 | 22.47 |
Enterprise value
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 1.92 | 2.91 |
| EV / EBITDA | 464.38 | 19.74 |
| EV / FCF | 413.15 | 27.89 |
Income (trailing twelve months)
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Revenue | $120.65M | $102.39M |
| Gross Profit | $75.00M | $60.36M |
| Operating Income | -$5.12M | -$4.31M |
| Pretax Income | -$2.91M | -$2.37M |
| Net Income | -$3.78M | -$6.57M |
| EBITDA | $500.00K | -$1.98M |
| EPS (Diluted) | -$0.27 | -$0.08 |
Margins
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 62.2% | 55.2% |
| Operating Margin | -4.24% | -6.04% |
| Pretax Margin | -2.41% | -4.11% |
| Profit Margin | -3.14% | -10.5% |
| EBITDA Margin | 0.41% | -2.67% |
| FCF Margin | 0.47% | 0.02% |
Returns
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -2.66% | -18.2% |
| Return on Assets (ROA) | -2.04% | -13.3% |
| Return on Invested Capital (ROIC) | -4.78% | -3.69% |
| Return on Capital Employed (ROCE) | -3.17% | -9.07% |
Growth
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 5.33% | 8.85% |
| Revenue Growth (3Y CAGR) | -0.30% | 7.08% |
| Revenue Growth (5Y CAGR) | -2.86% | 11.8% |
Balance sheet
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $38.41M | $36.66M |
| Net Cash (Debt) | $38.41M | $3.92M |
| Net Cash Per Share | $2.87 | $0.28 |
| Equity (Book Value) | $137.28M | $55.33M |
| Book Value Per Share | $10.26 | $2.87 |
| Tangible Book Value | $127.81M | $10.79M |
| Working Capital | $77.04M | $56.72M |
Financial position
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.48 | 2.48 |
| Quick Ratio | 3.05 | 1.53 |
Cash flow (trailing twelve months)
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $5.98M | -$566.22K |
| Capital Expenditures | -$5.42M | -$3.69M |
| Free Cash Flow | $562.00K | -$696.00K |
| FCF Per Share | $0.04 | -$0.02 |
Efficiency
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.65 | 0.58 |
| Inventory Turnover | 2.01 | 2.21 |
| Revenue Per Employee | $513.42K | $322.92K |
| Profits Per Employee | -$16.10K | -$51.88K |
| Employee Count | 235 | 185 |
Dividends and yields
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -1.40% | -6.88% |
| FCF Yield | 0.21% | -0.45% |
| Buyback Yield | 5.56% | 0.78% |
| Shareholder Yield | 5.56% | 0.80% |
Shares
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 13,383,000 | 44,302,700 |
| Shares Change (YoY) | -3.82% | 3.36% |
| Shares Change (QoQ) | 0.19% | 0.27% |
| Float | 11,116,400 | 37,462,700 |
| Shares Held by Insiders | 16.9% | 10.5% |
| Shares Held by Institutions | 91.9% | 63.5% |
Taxes
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Income Tax | $208.00K | $1.52M |
Scores
| Measure | Anika Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 5.03 | 1.95 |
| Piotroski F-Score | 6 | 5 |
| Beneish M-Score | -2.91 | -2.64 |
Calculated by StockData from Anika Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.